Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis
Pharmacokinetic and Pharmacodynamic Effects of Dorzagliatin in Pancreatic Insufficient-Cystic Fibrosis: A Randomized Double-blind, Cross-over Trial
Sponsor: University of Pennsylvania
Listed as NCT06995651, this PHASE1 trial focuses on Cystic Fibrosis-related Diabetes and Pancreatic Insufficiency and remains actively recruiting participants. Sponsored by University of Pennsylvania, it has been updated 6 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE1
▶ Show 1 earlier version
-
Jun 2025 — Jul 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .